Jennison Associates
MCRB icon

Jennison Associates’s Seres Therapeutics MCRB Stock Holding History

Jennison Associates’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69,618
Closed -$6.67M – 586
2023
Q2 		$6.67M Buy
69,618
+36,381
+109% +$3.96M 0.01% 405
2023
Q1 		$3.77M Sell
33,237
-185
-0.6% -$20K ﹤0.01% 448
2022
Q4 		$3.74M Buy
+33,422
New +$4.48M ﹤0.01% 436
2018
Q2 		– Sell
-10,510
Closed -$1.54M – 686
2018
Q1 		$1.54M Sell
10,510
-869
-8% -$167K ﹤0.01% 537
2017
Q4 		$2.31M Buy
+11,379
New +$2.34M ﹤0.01% 522
2016
Q3 		– Sell
-33,532
Closed -$19.5M – 674
2016
Q2 		$19.5M Buy
33,532
+13,469
+67% +$7.9M 0.02% 406
2016
Q1 		$10.7M Buy
20,063
+115
+0.6% +$60K 0.01% 452
2015
Q4 		$14M Buy
19,948
+363
+2% +$239K 0.01% 457
2015
Q3 		$11.6M Buy
19,585
+85
+0.4% +$69.3K 0.01% 497
2015
Q2 		$16.2M Buy
+19,500
New +$17M 0.01% 478

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Jennison Associates's MCRB Position: Q3 2023 in Review

Jennison Associates sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 69,618 shares — an estimated $6.67M sold.

Jennison Associates first reported a position in MCRB in Q2 2015 and held it in 10 quarters. The position peaked at $19.5M in Q2 2016. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Jennison Associates reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Jennison Associates sold 69,618 Seres Therapeutics shares in Q3 2023, an estimated $6.67M.
  • Jennison Associates first reported a position in Seres Therapeutics in Q2 2015 and held it in 10 quarters.
  • Jennison Associates's Seres Therapeutics position peaked at $19.5M in Q2 2016.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Jennison Associates's 13F filing for Q3 2023, filed 31 Oct 2023.